Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141 XCR1 dendritic cells

Gene Therapy

Volumn 19, Issue 10, 2012, Pages 1035-1040

  Silk, K M ^a   Silk, J D ^b   Ichiryu, N ^a   Davies, T J ^a   Nolan, K F ^a   Leishman, A J ^a   Carpenter, L ^c,d   Watt, S M ^c,d   Cerundolo, V ^b   Fairchild, P J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cross presentation; Dendritic cells; Induced pluripotent stem cells; Tumour immunotherapy

Indexed keywords

HLA A ANTIGEN; MELAN A; TUMOR ANTIGEN;

ARTICLE; BLOOD; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL LINE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; MONOCYTE; NORMAL HUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL;

ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, NEOPLASM; CELL DIFFERENTIATION; CROSS-PRIMING; DENDRITIC CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED;

IPS;

EID: 84867404077     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.177     Document Type: Article

References (29)

1. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010; 33: 464-478.
2. Engell-Noerregaard L, Hansen TH, Andersen MH, Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009; 58: 1 -14.
3. + T cells in patients with melanoma. J Immunol 2005; 175: 6169-6176. (Pubitemid 41508105)
4. Robson NC, Hoves S, Maraskovsky E, Schnurr M. Presentation oftumour antigens by dendritic cells and challenges faced. Curr Opin Immunol 2010; 22: 137-144.
5. + dendritic cells. J Exp Med 2010; 207: 1273-1281.
6. + dendritic cells. J Exp Med 2010; 207: 1283-1292.
7. Gallois A, Bhardwaj N. A needle in the 'cancer vaccine' haystack. Nat Med 2010; 16: 854-856.
8. + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207: 1247-1260.
9. + dendritic cells. J Exp Med 2010; 207: 1261 -1271.
10. + dendritic cells. J Exp Med 2010; 207: 1131-1134.
11. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861 -872. (Pubitemid 350138099)
12. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2007; 451: 141-146.
13. Carpenter L, Malladi R, Yang C-T, French A, Pilkington KJ, Forsey RW et al. Human induced pluripotent stem cells are capable of B-cell lymphopoiesis. Blood 2011; 117: 4008-4011.
14. + progenitors. J Clin Invest 2009; 119: 2818-2829.
15. Choi K-D, Vodyanik M, Slukvin II. Hematopoietic differentiation and production of mature myeloid cells from human pluripotent stem cells. Nat Protoc 2011; 6: 296-313.
16. Tseng S-Y, Nishimoto KP, Silk KM, Majumdar AS, Dawes GN, Waldmann H et al. Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells. Regen Med 2009; 4: 513-526.
17. + dendritic cells. J Immunol 2011; 186: 1503-1511.
18. Maurer T, Heit A, Hochrein H, Ampenberger F, O'Keeffe M, Bauer S etal. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur J Immunol 2002; 32: 2356-2364. (Pubitemid 34965899)
19. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005; 433: 887-892. (Pubitemid 40314900)
20. + T cells. Immunity 2009; 31: 823-833.
21. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers ofantigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998; 188: 1641 -1650. (Pubitemid 28516109)
22. Senju S, Haruta M, Matsumura K, Matsunaga S, Fukushima S, Ikeda T et al. Generation ofdendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy. Gene Ther 2011; 18: 874-883.
23. Fukuma D, Matsuyoshi H, Hirata S, Kurisaki A, Motomura Y, Yoshitake Y et al. Cancer prevention with semi-allogeneic ES cell-derived dendritic cells. Biochem Biophys Res Commun 2005; 335: 5-13. (Pubitemid 41350757)
24. Fabre JW. The allogeneic response and anti-tumor immunity. Nat Med 2001; 7: 649-652.
25. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008; 29: 44-56.
26. + Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009; 113: 6102-6111.
27. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40: 1830-1835.
28. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006; 107: 628-636. (Pubitemid 43076387)
29. Nishikawa S, Goldstein RA, Nierras CR. The promise of human induced pluripotent stem cells for research and therapy. Nature Rev Mol Cell Biol 2008; 9: 725-729.